122 related articles for article (PubMed ID: 1333274)
1. Experimental therapy in Hodgkin's disease.
Engert A; Pohl C; Diehl V
Ann Oncol; 1992 Sep; 3 Suppl 4():97-100. PubMed ID: 1333274
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
3. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
4. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
[TBL] [Abstract][Full Text] [Related]
5. Active specific immunotherapy of Hodgkin's lymphoma by an anti-idiotype vaccine against the Hodgkin-associated CD30 antigen.
Renner C; Pfreundschuh M; Diehl V; Pohl C
Ann N Y Acad Sci; 1993 Aug; 690():352-4. PubMed ID: 8396378
[No Abstract] [Full Text] [Related]
6. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
[TBL] [Abstract][Full Text] [Related]
7. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
9. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
[TBL] [Abstract][Full Text] [Related]
10. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P
Int J Cancer; 1995 Oct; 63(2):304-9. PubMed ID: 7591221
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
[TBL] [Abstract][Full Text] [Related]
12. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
Sahin U; Hartmann F; Senter P; Pohl C; Engert A; Diehl V; Pfreundschuh M
Cancer Res; 1990 Nov; 50(21):6944-8. PubMed ID: 2170012
[TBL] [Abstract][Full Text] [Related]
13. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
[TBL] [Abstract][Full Text] [Related]
14. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
15. Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
Pohl C; Sieber M; Diehl V; Pfreundschuh M
Anticancer Res; 1991; 11(3):1115-24. PubMed ID: 1653553
[TBL] [Abstract][Full Text] [Related]
16. Mimicry of the Hodgkin-associated IRAC antigen by an anti-idiotype network: potential use in active immunotherapy of Hodgkin's lymphoma.
Schobert I; Renner C; Pfreundschuh M; Diehl V; Pohl C
Leuk Lymphoma; 1994 May; 13(5-6):429-40. PubMed ID: 8069188
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma.
Borchmann P; Schnell R; Schulz H; Engert A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1262-7. PubMed ID: 15648946
[TBL] [Abstract][Full Text] [Related]
18. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
[TBL] [Abstract][Full Text] [Related]
19. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
Pohl C; Renner C; Schwonzen M; Sieber M; Lorenz P; Pfreundschuh M; Diehl V
Int J Cancer; 1992 Apr; 50(6):958-67. PubMed ID: 1313400
[TBL] [Abstract][Full Text] [Related]
20. Current strategies of antibody-based treatment in Hodgkin's disease.
Schnell R; Borchmann P; Schulz H; Engert A
Ann Oncol; 2002; 13 Suppl 1():57-66. PubMed ID: 12078905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
